NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT02354547 2025-05-30
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT00117013 2017-07-02
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00422682 2016-06-10
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00382733 2013-07-22
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
Accelerated Community Oncology Research Network
Phase 1/2 Completed
NCT00611468 2011-08-22
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
Accelerated Community Oncology Research Network
Phase 1 Completed
NCT00193583 2011-05-04
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00412503 2009-08-07
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT00193570 2009-01-23
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00006199 2005-06-24
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
National Center for Research Resources (NCRR)
Phase 1 Unknown